Updated Data Confirm Clinical Benefit of Novel Immunotherapy Combos in HCC
April 6th 2021
Daniel Lin, MD, MS, highlights pivotal trials evaluating immunotherapy regimens in patients with hepatocellular carcinoma, remaining sequencing questions, and emerging regimens that are showing promise.